Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Sektion für Stammzell- und Immuntherapie > Publikationen / Publications > 2010 - 2014

Publikationen / Publications

2014

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N; German High-Grade Lymphoma Study Group.  Lancet Oncol. (2014) 15(7): 757-66 (PubMed)

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. Haematologica. (2014) 99(2): 232-42 (PubMed)

Epidermal Growth Factor Receptor Targeting IgG3 Triggers Complement-Mediated Lysis of Decay-Accelerating Factor Expressing Tumor Cells through the Alternative Pathway Amplification Loop. Rösner T, Lohse S, Peipp M, Valerius T, Derer S. J Immunol. (2014) 193(3): 1485-95 (PubMed)

Complement in antibody-based tumor therapy. Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T. Crit Rev Immunol. (2014) 34(3): 199-214 (PubMed)

The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. Staudinger M, Glorius P, Burger R, Kellner C, Klausz K, Günther A, Repp R, Klapper W, Gramatzki M, Peipp M. Blood Cancer J. (2014) 4, e219 (PubMed)

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization. Derer S, Kellner C, Rösner T, Klausz K, Glorius P, Valerius T, Peipp M. Methods Mol Biol. (2014), 1131: 525-40 (PubMed)

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal, U, Desjarlais JR, Humpe A, Valerius T, Peipp M. MAbs. (2014) 6(2): 409-21 (PubMed)

Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, Adam-Klages S, Röcken C, Becker T, Vogel I, Weisner D, Freitag-Wolf S, Gramatzki M, Kabelitz D, Wesch D. Cancer Res (2014) 74(5): 1349-60  (PubMed)

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Kellner C, Derer S, Valerius T, Peipp M. Methods (2014), 65(1): 105-13 (PubMed)

2013

Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis. Humpe A, Buwitt-Beckmann U, Schub N, Gramatzki M, Günther A. Transfus Med Hemother. (2013) 40(4): 251-7 (PubMed)

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Fürst D, Müller C, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B, Schrezenmeier H, Schwarz K, Mytilineos J. Blood. (2013) 122(18): 3220-9 (PubMed)

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C. J Clin Oncol. (2013) 31(26): 3259-71 (PubMed)

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhäuser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schäfer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, Horst HA, Gramatzki M, Brück P, Serve H, Hoelzer D, Gökbuget N, Ottmann OG; GMALL Study Group. Leukemia. (2013) 27(6): 1254-62  (PubMed)

Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhäuser M, Ehninger G, Dolan K, Gramatzki M, Kolb HJ, Heußner P, Wilhelm H, Beelen DW, Schulz-Kindermann F, Zander AR, Koch U, Mehnert A. Psychooncology. (2013) 22(7): 1509-16. (PubMed)

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, Leusen JH, Valerius T. MAbs (2013) 5(6): 936-45 (PubMed)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies. Derer S, Lohse S, Valerius T. Oncoimmunology. (2013) 2(5): e24052 (PubMed)

Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis. Koch T, Derer S, Staudinger M, Rossen K, Glorius P, Peipp M, Kellner C, Kunzendorf U, Valerius T, Dechant M. Am J Nephrol. (2013) 38(5): 379-87 (PubMed)

Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis. Humpe A, Buwitt-Beckmann U, Schub N, Gramatzki M, Günther A. Transfus Med Hemother. (2013) 40(4): 251-7 (PubMed)

Strategies for purging CD96+ stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia. Staudinger M, Humpe A, Gramatzki M. Oncoimmunology. (2013), 2(6): e24500. (PubMed)

In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapy. Gahn B, Staudinger M, Woester K, Wellnitz D, Boettcher S, Gramatzki M, Kneba M. J Thorac Dis. (2013) 5(3): 240-50. (PubMed)

Allogeneic Stem Cell Transplantation with BEAM and Alemtuzumab Conditioning Immediately after Remission Induction Has Curative Potential in Advanced T-Cell Non-Hodgkin's Lymphoma. Czajczynska A, Günther A, Repp R, Humpe A, Schub N, Raff T, Nickelsen M, Schrauder A, Schrappe M, Kneba M,  Gramatzki M. Biol Blood Marrow Transplant. (2013) 19(11): 1632-7  (PubMed)

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype. Kellner C, Gramatzki M, Peipp M. Oncoimmunology. (2013) 2(6): e24481. (PubMed)

IgA EGFR antibodies mediate tumour killing in vivo. Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH. EMBO Mol Med. (2013) 5(8): 1213-26. (PubMed)

An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. Rösner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, Peipp M, Valerius T. Br J Haematol. (2013) 161(2): 282-6. (PubMed)

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Kellner C, Zhukovsky EA, Potzke A, Bruggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M, Peipp M. Leukemia. (2013) 27(7): 1595-8. (PubMed)

The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M. Leukemia. (2013) 27(1): 190-201 (PubMed)

ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates. Trad A, Hansen HP, Shomali M, Peipp M, Klausz K, Hedemann N, Yamamoto K, Mauermann A, Desel C, Lorenzen I, Lemke H, Rose-John S, Grotzinger J. Cancer Immunol Immunother. (2013) 62(3): 411-21 (PubMed)

2012

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96. Mohseni Nodehi S, Repp R, Kellner C, Brautigam J, Staudinger M, Schub N, Peipp M, Gramatzki M, Humpe A. PLoS One. (2012) 7(8): e42426. (PubMed)

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, Valerius T. J Biol Chem. (2012), 287(30): 25139-50 (PubMed)

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M. J Immunol. (2012) 189(10): 5037-46 (PubMed)

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, Repp R, Humpe A, Gramatzki M, Peipp M. Leukemia (2012) 26(4): 830-4 (PubMed)

Direct volumetric flow cytometric quantitation of CD34+ stem and progenitor cells. Gutensohn K, Nikolitsis A, Gramatzki M, Spitzer D, Buwitt-Beckmann U, Humpe A. Transfus Med. (2012), 22(3): 205-10 (PubMed)

Flow cytometric analyses of CD34+ cells with inclusion of internal positive controls. Gutensohn K, Jessen M, Ketels A, Gramatzki M, Humpe A. Transfusion. (2012) 52(2): 284-90 (PubMed)

Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function. Derer S, Kellner C, Berger S, Valerius T, Peipp M. Methods Mol Biol. (2012) 907: 519-36 (PubMed)

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPbeta-dependent suppression of EGFR expression. Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T. Neoplasia. (2012) 14(3): 190-205 (PubMed)

Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, Peipp M, Valerius, T. J Immunol. (2012) 189(11): 5230-9 (PubMed)

Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Tagliaferri P. Current Cancer Drug Targets. (2012) 12 (7): 814-822 (PubMed)

2011

Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Schub N, Günther A, Schrauder A, Claviez A, Ehlert C, Gramatzki M, Repp R. Bone Marrow Transplant. (2011) 46(1): 143-7 (PubMed)

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M. J Immunol Methods. (2011) 373(1-2): 67-78 (PubMed)

Molecular engineering to improve antibodies' anti-lymphoma activity. Peipp M, van de Winkel JG, Valerius T.  Best Pract Res Clin Haematol. (2011) 24(2): 217-29 (PubMed)

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T. J Immunol. (2011) 186(6): 3770-8 (PubMed)

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T. Cancer Sci. (2011) 102(10):  1761-8 (PubMed)

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S, Glorius P, Muskulus A, de Goeij BE, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M. J Immunol Methods. (2011) 371(1-2): 122-33 (PubMed)

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. J Immunol. (2011) 186(3): 1840-8. (PubMed)

Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, Fey GH. Cancer Letters. (2011) 303(2): 128-39 (PubMed)

2010

Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M. J Immunol. (2010) 184(1): 512-20 (PubMed)

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, Lazar GA, Schneider-Merck T, Peipp M, Valerius T. Cancer Sci. (2010) 101(5): 1080-8 (PubMed)

Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies. Lohse S, Peipp M, Beyer T, Valerius T, Dechant M. Arch Immunol Ther Exp (Warsz). (2010) 58(4): 303-12 (PubMed)

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, Zhukovsky EA. Blood. (2010) 116(16):  3004-12 (PubMed)

A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, Stockmeyer B. J Immunol. (2010) 184(3): 1210-7 (PubMed)

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M. Int J Cancer. (2010) 126(1): 239-46 (PubMed)